Bausch & Lomb Corp (BLCO) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions and 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.3M sold). Latest close $20.95 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 29, 2026 · Congress to Nov 16, 2026.
Oaktree Capital Management · Icahn Capital Management · Third Point — 3 tracked funds hold BLCO. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 1 sale ($2.3M). Insider trading
ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Warby Parker Inc. (WRBY) · National Vision Holdings, Inc. (EYE) · THERMO FISHER SCIENTIFIC INC. (TMO) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Oaktree Capital Management | 0.79% | 3,441,042 | ADDED (+1.7%) |
| Icahn Capital Management | 0.70% | 3,500,000 | HELD Q3 filed Nov 13 |
| Third Point | 0.03% | 85,000 | NEW Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +25.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 98 of 8,857 filers |
| Long-only filers among them | 98 |
| Change vs 2026 Q1 | +2 net · 98 entered · 96 exited |
| Shares reported, all filers | 38,180,005 |
| Reported value, all filers | $597.2M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Ophthalmic Goods (SIC 3851) |
| Revenue · FY2025 | $5.1B |
| Net income · FY2025 | $-360.0M |
| Total assets · FY2025 | $14.0B |
| Shares outstanding | 357,497,374 |
| Market cap (at latest close) | $7.5B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 21, 2026.
| Shares short · Oct 15, 2026 | 2,542,763 |
| Share of shares outstanding | 0.71% |
| Days to cover | 3.60 |
Shares short at recent settlements — Jul 31, 2026: 3.0M · Aug 14, 2026: 3.2M · Aug 31, 2026: 3.4M · Sep 15, 2026: 3.2M · Sep 30, 2026: 3.0M · Oct 15, 2026: 2.5M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 21, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 1K · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 21, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($2.3M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | Munsch Frederick | SVP, Controller and CAO | Sell | 112,015 | $20.48 | $2.3M | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Ling Karen | Former Director | 4,500 | $75.7K | Sep 28, 2026 | SEC filing |
| Aug 11, 2026 | Munsch Frederick | Officer | 52,900 | $887.9K | Aug 10, 2026 | SEC filing |
| Aug 10, 2026 | Munsch Frederick | Former Officer | 52,900 | $887.9K | Aug 10, 2026 | SEC filing |
| Aug 7, 2026 | VON ESCHENBACH ANDREW C. | Former Director | 6,059 | $100.4K | Aug 7, 2026 | SEC filing |
| Aug 6, 2026 | VON ESCHENBACH ANDREW C. | Former Director | 12,500 | $206.2K | Aug 6, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Ophthalmic Goods (SIC 3851). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 47 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (19), Medical/Disease Research/Clinical Labs (12), Budget/Appropriations (11).
Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Financial Screens
· Growth — Revenue up every year for 5 straight years
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $5.1B · 5-yr revenue CAGR: 8.4% · Straight growth years: 5
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q1, ranked #2 of 50.
Also held by the tracked funds that hold BLCO — ranked by lift, the co-holding pattern described in Methodology: ALCON INC (ALC) · COOPER COMPANIES, INC. (COO) · Warby Parker Inc. (WRBY) · National Vision Holdings, Inc. (EYE) · THERMO FISHER SCIENTIFIC INC. (TMO) · INTUITIVE SURGICAL INC (ISRG) · Medtronic plc (MDT) · WATERS CORP /DE/ (WAT).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Oct 28, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 28, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers | SEC filing |
| Oct 13, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
ALCON INC (ALC) · Track Record: how the signals scored · Practice timing on BLCO
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.